^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CDDD11-8

    i
    Other names: CDDD11-8
    Company:
    University of South Australia
    Drug class:
    FLT3 inhibitor, CDK9 inhibitor
    Related drugs:
    1year
    Selective inhibition of CDK9 in triple negative breast cancer. (PubMed, Oncogene)
    Orally administered CDDD11-8 also inhibited growth of mammary intraductal TNBC xenograft tumours with no overt toxicity in vivo (mice) or ex vivo (human breast tissues). In conclusion, our studies indicate that CDK9 is a viable therapeutic target in TNBC and that CDDD11-8, a novel selective CDK9 inhibitor, has efficacy in TNBC without apparent toxicity to normal tissues.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CDK9 (Cyclin Dependent Kinase 9)
    |
    MYC amplification
    |
    CDDD11-8